Anti-tumoral effects of miR-3189-3p in glioblastoma

Journal of Biological Chemistry

Volumn 290, Issue 13, 2015, Pages 8067-8080

  Jeansonne, Duane ^a   DeLuca, Mariacristina ^a,b   Marrero, Luis ^a,b   Lassak, Adam ^a   Pacifici, Marco ^a   Wyczechowska, Dorota ^a   Wilk, Anna ^a   Reiss, Krzysztof ^a   Peruzzi, Francesca ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; BIOLOGY;

GLIOBLASTOMA CELLS; GLIOBLASTOMAS; GROWTH DIFFERENTIATION; THERAPEUTIC PROPERTIES; TUMOR SUPPRESSOR ACTIVITY;

TUMORS;

ANTINEOPLASTIC AGENT; ARGONAUTE 2 PROTEIN; FENOFIBRATE; GROWTH DIFFERENTIATION FACTOR 15; MICRORNA 3189 3P; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; GDF15 PROTEIN, HUMAN; MICRORNA; MIRN3189 MICRORNA, HUMAN; P63RHOGEF PROTEIN, HUMAN; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; SF3B2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; FEMALE; GENE; GENE TARGETING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; P63RHOGEF GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SF3B2 GENE; ANIMAL; BINDING SITE; BIOSYNTHESIS; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ANIMALS; BASE SEQUENCE; BINDING SITES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MICE, NUDE; MICRORNAS; NEOPLASM TRANSPLANTATION; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; RNA INTERFERENCE; RNA-BINDING PROTEINS;

EID: 84925708208     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.633081     Document Type: Article

References (33)

1. Nakada, M., Nakada, S., Demuth, T., Tran, N. L., Hoelzinger, D. B., and Berens, M. E. (2007) Molecular targets of glioma invasion. Cell. Mol. Life Sci. 64, 458-478
2. Nagasawa, D. T., Chow, F., Yew, A., Kim, W., Cremer, N., and Yang, I. (2012) Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg. Clin. N. Am. 23, 307-322, ix
3. Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., Bromberg, J. E., Hau, P., Mirimanoff, R. O., Cairncross, J. G., Janzer, R. C., and Stupp, R. (2005)MGMTgene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003
4. Jeansonne, D., Pacifici, M., Lassak, A., Reiss, K., Russo, G., Zabaleta, J., and Peruzzi, F. (2013) Differential effects of MicroRNAs on glioblastoma growth and migration. Genes 4, 46-64
5. Drukala, J., Urbanska, K., Wilk, A., Grabacka, M., Wybieralska, E., Del Valle, L., Madeja, Z., and Reiss, K. (2010) ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARα-mediated inhibition of glioma cell motility in vitro. Mol. Cancer 9, 159
6. Wilk, A., Wyczechowska, D., Zapata, A., Dean, M., Mullinax, J., Marrero, L., Parsons, C., Peruzzi, F., Culicchia, F., Ochoa, A., Grabacka, M., and Reiss, K. (2014) Molecular mechanisms of fenofibrate-induced metabolic catastrophe and glioblastoma cell death. Mol. Cell. Biol. 35, 182-198
7. Mimeault, M., and Batra, S. K. (2010) Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J. Cell. Physiol. 224, 626-635
8. Wang, X., Baek, S. J., and Eling, T. E. (2013) The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem. Pharmacol. 85, 597-606
9. Eling, T. E., Baek, S. J., Shim, M., and Lee, C. H. (2006) NSAID activated gene (NAG-1), a modulator of tumorigenesis. J. Biochem. Mol. Biol. 39, 649-655
10. Kim, J. M., Kosak, J. P., Kim, J. K., Kissling, G., Germolec, D. R., Zeldin, D. C., Bradbury, J. A., Baek, S. J., and Eling, T. E. (2013) NAG-1/GDF15 transgenic mouse has less white adipose tissue and a reduced inflammatory response. Mediators Inflamm. 2013, 641851
11. Li, A., Walling, J., Ahn, S., Kotliarov, Y., Su, Q., Quezado, M., Oberholtzer, J. C., Park, J., Zenklusen, J. C., and Fine, H. A. (2009) Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res. 69, 2091-2099
12. Chiu, S. C., Wang, M. J., Yang, H. H., Chen, S. P., Huang, S. Y., Chen, Y. L., Lin, S. Z., Harn, H. J., and Pang, C. Y. (2011) Activation of NAG-1 via JNK signaling revealed an isochaihulactone-triggered cell death in human LNCaP prostate cancer cells. BMC Cancer 11, 146
13. Yoshioka, H., Kamitani, H., Watanabe, T., and Eling, T. E. (2008) Nonsteroidal anti-inflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J. Biol. Chem. 283, 33129-33137
14. Eletto, D., Russo, G., Passiatore, G., Del Valle, L., Giordano, A., Khalili, K., Gualco, E., and Peruzzi, F. (2008) Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J. Cell. Physiol. 216, 764-770
15. Pacifici, M., Delbue, S., Ferrante, P., Jeansonne, D., Kadri, F., Nelson, S., Velasco-Gonzalez, C., Zabaleta, J., and Peruzzi, F. (2013) Cerebrospinal fluid miRNA profile in HIV-encephalitis. J. Cell. Physiol. 228, 1070-1075
16. Rom, S., Rom, I., Passiatore, G., Pacifici, M., Radhakrishnan, S., Del Valle, L., Piña-Oviedo, S., Khalili, K., Eletto, D., and Peruzzi, F. (2010) CCL8/ MCP-2 is a target for mir-146a in HIV-1-infected human microglial cells. FASEB J. 24, 2292-2300
17. Curtale, G., Mirolo, M., Renzi, T. A., Rossato, M., Bazzoni, F., and Locati, M. (2013) Negative regulation of Toll-like receptor 4 signaling by IL-10-dependent microRNA-146b. Proc. Natl. Acad. Sci. U.S.A. 110, 11499-11504
18. Marrero, L., Wyczechowska, D., Musto, A. E., Wilk, A., Vashistha, H., Zapata, A., Walker, C., Velasco-Gonzalez, C., Parsons, C., Wieland, S., Levitt, D., Reiss, K., and Prakash, O. (2014) Therapeutic efficacy of aldoxorubicin in an intracranial xenograft mouse model of human glioblastoma. Neoplasia 16, 874-882
19. Orr, S. J., Boutz, D. R., Wang, R., Chronis, C., Lea, N. C., Thayaparan, T., Hamilton, E., Milewicz, H., Blanc, E., Mufti, G. J., Marcotte, E. M., and Thomas, N. S. (2012) Proteomic and protein interaction network analysis of human T lymphocytes during cell-cycle entry. Mol. Syst. Biol. 8, 573
20. Hayashi, A., Hiatari, R., Tsuji, T., Ohashi, K., and Mizuno, K. (2013) p63RhoGEF-mediated formation of a single polarized lamellipodium is required for chemotactic migration in breast carcinoma cells. FEBS Lett. 587, 698-705
21. Shimizu, S., Kadowaki, M., Yoshioka, H., Kambe, A., Watanabe, T., Kinyamu, H. K., and Eling, T. E. (2013) Proteasome inhibitor MG132 induces NAG-1/GDF15 expression through the p38 MAPK pathway in glioblastoma cells. Biochem. Biophys. Res. Commun. 430, 1277-1282
22. Araki, H., Tamada, Y., Imoto, S., Dunmore, B., Sanders, D., Humphrey, S., Nagasaki, M., Doi, A., Nakanishi, Y., Yasuda, K., Tomiyasu, Y., Tashiro, K., Print, C., Charnock-Jones, D. S., Kuhara, S., and Miyano, S. (2009) Analysis of PPARα-dependent and PPARα-independent transcript regulation following fenofibrate treatment of human endothelial cells. Angiogenesis 12, 221-229
23. Wilk, A., Urbanska, K., Grabacka, M., Mullinax, J., Marcinkiewicz, C., Impastato, D., Estrada, J. J., and Reiss, K. (2012) Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro. Cell Cycle 11, 2660-2671
24. Stark, M. S., Tyagi, S., Nancarrow, D. J., Boyle, G. M., Cook, A. L., Whiteman, D. C., Parsons, P. G., Schmidt, C., Sturm, R. A., and Hayward, N. K. (2010) Characterization of the melanoma miRNAome by deep sequencing. PloS ONE 5, e9685
25. Sivadas, V. P., George, N. A., Kattoor, J., and Kannan, S. (2013) Novel mutations and expression alterations in SMAD3/TGFBR2 genes in oral carcinoma correlate with poor prognosis. Genes Chromosomes Cancer 52, 1042-1052
26. Lai, E. C. (2003) microRNAs: runts of the genome assert themselves. Curr. Biol. 13, R925-936
27. Okamura, K., Hagen, J. W., Duan, H., Tyler, D. M., and Lai, E. C. (2007) The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell 130, 89-100
28. Swenson-Fields, K. I., Sandquist, J. C., Rossol-Allison, J., Blat, I. C., Wennerberg, K., Burridge, K., and Means, A. R. (2008) MLK3 limits activatedG αq signaling to Rho by binding to p63RhoGEF. Mol. Cell 32, 43-56
29. Tang, X., Jin, R., Qu, G., Wang, X., Li, Z., Yuan, Z., Zhao, C., Siwko, S., Shi, T., Wang, P., Xiao, J., Liu, M., and Luo, J. (2013) GPR116, an adhesion G-protein-coupled receptor, promotes breast cancer metastasis via the Gαq-p63RhoGEF-Rho GTPase pathway. Cancer Res. 73, 6206-6218
30. DeGregori, J., Kowalik, T., and Nevins, J. R. (1995) Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell Biol. 15, 4215-4224
31. Matsumura, I., Tanaka, H., and Kanakura, Y. (2003) E2F1 and c-Myc in cell growth and death. Cell Cycle 2, 333-338
32. Urbanska, K., Pannizzo, P., Grabacka, M., Croul, S., Del Valle, L., Khalili, K., and Reiss, K. (2008) Activation of PPARα inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines. Int. J. Cancer 123, 1015-1024
33. Panigrahy, D., Kaipainen, A., Huang, S., Butterfield, C. E., Barnés, C. M., Fannon, M., Laforme, A. M., Chaponis, D. M., Folkman, J., and Kieran, M. W. (2008) PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl. Acad. Sci. U.S.A. 105, 985-990